Biologic and Clinical Perspectives on Thyroid Cancer

New England Journal of Medicine
375, 2306-2307
DOI: 10.1056/nejmc1613118

Citation Report

#	Article	IF	Citations
1	The Increased Incidence of Thyroid Cancer Is Worldwide. Clinical Thyroidology, 2017, 29, 11-12.	0.0	4
2	The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer. Best Practice and Research in Clinical Endocrinology and Metabolism, 2017, 31, 307-318.	2.2	26
3	MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN. Oncogene, 2018, 37, 3369-3383.	2.6	77
4	Thyroid Cancer: Is It All in the Genes?. Journal of the National Cancer Institute, 2018, 110, 327-328.	3.0	2
5	The role of SMAD3 in the genetic predisposition to papillary thyroid carcinoma. Genetics in Medicine, 2018, 20, 927-935.	1.1	12
6	INAVA promotes aggressiveness of papillary thyroid cancer by upregulating MMP9 expression. Cell and Bioscience, 2018, 8, 26.	2.1	12
7	Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial. Diabetes Care, 2018, 41, 2404-2413.	4.3	32
8	ANGPTL4 variants and their haplotypes are associated with serum lipid levels, the risk of coronary artery disease and ischemic stroke and atorvastatin cholesterol-lowering responses. Nutrition and Metabolism, 2018, 15, 70.	1.3	12
9	Quantitative Proteomics Analysis of Sporadic Medullary Thyroid Cancer Reveals FN1 as a Potential Novel Candidate Prognostic Biomarker. Oncologist, 2018, 23, 1415-1425.	1.9	36
10	Lenvatinib-Associated Cervical Artery Dissections in a Patient with Radioiodine-Refractory Metastatic Papillary Thyroid Carcinoma. Frontiers in Medicine, 2017, 4, 220.	1.2	4
11	Synchronous Independent Papillary Thyroid Carcinomas in Struma Ovarii and the Thyroid Gland With Different RAS Mutations. Journal of the Endocrine Society, 2018, 2, 944-948.	0.1	13
12	Frequent and Rare HABP2 Variants Are Not Associated with Increased Susceptibility to Familial Nonmedullary Thyroid Carcinoma in the Spanish Population. Hormone Research in Paediatrics, 2018, 89, 397-407.	0.8	3
13	Long-term outcome of rare oncocytic papillary (HÃ¼rthle cell) thyroid carcinoma following (adjuvant) initial radioiodine therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2526-2535.	3.3	14
14	Leukocyte Mitochondrial DNA Copy Number and Risk of Thyroid Cancer: A Two-Stage Case-Control Study. Frontiers in Endocrinology, 2019, 10, 421.	1.5	13
15	Patients Aged â‰¥55 Years With Stage T1-2N1M1 Differentiated Thyroid Cancer Should Be Downstaged in the Eighth Edition AJCC/TNM Cancer Staging System. Frontiers in Oncology, 2019, 9, 1093.	1.3	5
16	Genomic and Transcriptomic Characterization of Papillary Microcarcinomas With Lateral Neck Lymph Node Metastases. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4889-4899.	1.8	26
17	Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-Up. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4087-4100.	1.8	100
18	Mouse Models as a Tool for Understanding Progression in Braf^{V600E}-Driven Thyroid Cancers. Endocrinology and Metabolism, 2019, 34, 11.	1.3	14

#	Article	IF	Citations
19	Clinicopathological predictors of occult lateral neck lymph node metastasis in papillary thyroid cancer: A metaâ€analysis. Head and Neck, 2019, 41, 2441-2449.	0.9	38
20	Identification of RNA Expression Profiles in Thyroid Cancer to Construct a Competing Endogenous RNA (ceRNA) Network of mRNAs, Long Noncoding RNAs (lncRNAs), and microRNAs (miRNAs). Medical Science Monitor, 2019, 25, 1140-1154.	0.5	31
21	Multi-omics Signatures and Translational Potential to Improve Thyroid Cancer Patient Outcome. Cancers, 2019, 11, 1988.	1.7	21
22	Mutations of genes including DNMT3A detected by next-generation sequencing in thyroid cancer. Cancer Biology and Therapy, 2019, 20, 240-246.	1.5	7
23	Linc00210 enhances the malignancy of thyroid cancer cells by modulating miRâ€195â€5p/IGF1R/Akt axis. Journal of Cellular Physiology, 2020, 235, 1001-1012.	2.0	21
24	Therapeutic breakthroughs for metastatic thyroid cancer. Nature Reviews Endocrinology, 2020, 16, 77-78.	4.3	31
25	Apatinib combined with paclitaxel-based chemotherapy in patients with taxane-resistant advanced gastric cancer: a single-arm exploratory study. Annals of Translational Medicine, 2020, 8, 1233-1233.	0.7	8
26	Detection of BRAFV600E in Liquid Biopsy from Patients with Papillary Thyroid Cancer Is Associated with Tumor Aggressiveness and Response to Therapy. Journal of Clinical Medicine, 2020, 9, 2481.	1.0	25
27	LncRNA SNHG3, a potential oncogene in human cancers. Cancer Cell International, 2020, 20, 536.	1.8	41
28	p21-Activated Kinases in Thyroid Cancer. Endocrinology, 2020, 161, .	1.4	8
31	Tumor Size is an Independent Predictor of Mortality Risk in Differentiated Thyroid Cancer Patients with T4 Disease. Endocrine Practice, 2020, 26, 499-507.	1.1	4
32	Long-term progression of non-invasive follicular thyroid neoplasm with papillary-like nuclear features: A single-center retrospective study of the French Marneâ€“Ardennes thyroid cancer registry. Annales D'Endocrinologie, 2020, 81, 34-38.	0.6	3
33	The Long Non-Coding RNA Prader Willi/Angelman Region RNA5 (PAR5) Is Downregulated in Anaplastic Thyroid Carcinomas Where It Acts as a Tumor Suppressor by Reducing EZH2 Activity. Cancers, 2020, 12, 235.	1.7	39
34	Glypican 2 regulates cell proliferation and metastasis in thyroid cancer cells. Molecular and Cellular Toxicology, 2020, 16, 203-209.	0.8	2
35	Oncogenic pseudogene DUXAP10 knockdown suppresses proliferation and invasion and induces apoptosis of papillary thyroid carcinoma cells by inhibition of Akt/mTOR pathway. Clinical and Experimental Pharmacology and Physiology, 2020, 47, 1473-1483.	0.9	11
36	Ropivacaine inhibits proliferation, invasion, migration and promotes apoptosis of papillary thyroid cancer cells via regulating <scp>ITGA2</scp> expression. Drug Development Research, 2020, 81, 700-707.	1.4	16
37	Expression of Caveolin-1 Is Associated With Thyroid Function in Patients With Human Papillary Thyroid Carcinoma. Dose-Response, 2020, 18, 155932582091933.	0.7	1
38	Somatic Mutation Profiling of Papillary Thyroid Carcinomas by Whole-exome Sequencing and Its Relationship with Clinical Characteristics. International Journal of Medical Sciences, 2021, 18, 2532-2544.	1.1	5

#	Article	IF	Citations
39	Endocrine and Metabolic Diseases. , 2021, , 665-716.		0
40	Concomitant Pathogenic Mutations and Fusions of Driver Oncogenes in Tumors. Frontiers in Oncology, 2020, 10, 544579.	1.3	2
41	Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS. Theranostics, 2021, 11, 6251-6277.	4.6	59
42	Digoxin treatment reactivates in vivo radioactive iodide uptake and correlates with favorable clinical outcome in nonâ€medullary thyroid cancer. Cellular Oncology (Dordrecht), 2021, 44, 611-625.	2.1	8
43	Do Molecular Profiles of Primary Versus Metastatic Radioiodine Refractory Differentiated Thyroid Cancer Differ?. Frontiers in Endocrinology, 2021, 12, 623182.	1.5	10
44	Thyroid Parenchyma Microcalcifications on Ultrasound for Predicting Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Prospective Multicenter Study in China. Frontiers in Oncology, 2021, 11, 609075.	1.3	8
45	Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model. International Journal of Molecular Sciences, 2021, 22, 3031.	1.8	9
46	Identification of Key Functional Gene Signatures Indicative of Dedifferentiation in Papillary Thyroid Cancer. Frontiers in Oncology, 2021, 11, 641851.	1.3	2
47	Mixed medullaryâ€papillary thyroid carcinoma with mixed lymph node metastases: A case report. Clinical Case Reports (discontinued), 2021, 9, e04165.	0.2	6
48	Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers. Endocrine-Related Cancer, 2021, 28, 391-402.	1.6	10
49	Aberrant expression of five miRNAs in papillary thyroid carcinomas. Journal of Clinical Laboratory Analysis, 2021, 35, e23907.	0.9	6
50	T cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis. Diagnostic Pathology, 2021, 16, 84.	0.9	7
51	Identification of SPRY4 as a Novel Candidate Susceptibility Gene for Familial Nonmedullary Thyroid Cancer. Thyroid, 2021, 31, 1366-1375.	2.4	9
52	Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers. Journal of Clinical Investigation, 2018, 128, 4086-4097.	3.9	49
53	Integrated bioinformatics analysis of the association between apolipoprotein E expression and patient prognosis in papillary thyroid carcinoma. Oncology Letters, 2020, 19, 2295-2305.	0.8	3
54	TFE3 Regulates the Function of the Autophagy-Lysosome Pathway to Drive the Invasion and Metastasis of Papillary Thyroid Carcinoma. Analytical Cellular Pathology, 2021, 2021, 1-11.	0.7	5
55	Prognostic Value of Preoperative Serum Calcitonin Levels for Predicting the Recurrence of Medullary Thyroid Carcinoma. Frontiers in Endocrinology, 2021, 12, 749973.	1.5	11
56	GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer. Oncotarget, 2019, 10, 4107-4124.	0.8	5

#	Article	IF	Citations
57	Comparison of Cytologic Reports of Fine-Needle Aspiration of Thyroid Nodules with Pathologic Results of Thyroid Surgery. Avicenna Journal of Clinical Medicine, 2019, 26, 20-25.	0.1	0
60	Pulmonary Function in Patients With Multiple Endocrine Neoplasia 2B. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2919-2928.	1.8	0
61	Overexpression of novel long intergenic nonâ€'coding RNA LINC02454 is associated with a poor prognosis in papillary thyroid cancer. Oncology Reports, 2020, 44, 1489-1501.	1.2	9
62	Impact of Lin28 on lymph node metastasis in papillary thyroid carcinoma. Oncology Letters, 2020, 21, 97.	0.8	1
63	DNAJB11 predicts a poor prognosis and is associated with immune infiltration in thyroid carcinoma: a bioinformatics analysis. Journal of International Medical Research, 2021, 49, 030006052110537.	0.4	3
64	Prognosis of FTC compared to PTC and FVPTC: findings based on SEER database using propensity score matching analysis. American Journal of Cancer Research, 2018, 8, 1440-1448.	1.4	7
65	Active surveillance for young patients with insular thyroid cancer: an initial and novel finding. American Journal of Translational Research (discontinued), 2019, 11, 176-187.	0.0	1
66	Genetic differences in follicular thyroid carcinoma between Asian and Western countries: a systematic review. Gland Surgery, 2020, 9, 1813-1826.	0.5	0
67	Clinico-radiological features of brain metastases from thyroid cancer. Medicine (United States), 2021, 100, e28069.	0.4	8
68	Effects of Anti-Cancer Drug Sensitivity-Related Genetic Differences on Therapeutic Approaches in Refractory Papillary Thyroid Cancer. International Journal of Molecular Sciences, 2022, 23, 699.	1.8	5
69	Genetic differences in follicular thyroid carcinoma between Asian and Western countries: a systematic review. Gland Surgery, 2020, 9, 1813-1826.	0.5	6
70	Surgery and Radioactive Iodine Therapeutic Strategy for Patients Greater Than 60 Years of Age with Differentiated Thyroid Cancer. Journal of Healthcare Engineering, 2022, 2022, 1-9.	1.1	1
71	Is Maintaining Thyroid-Stimulating Hormone Effective in Patients Undergoing Thyroid Lobectomy for Low-Risk Differentiated Thyroid Cancer? A Systematic Review and Meta-Analysis. Cancers, 2022, 14, 1470.	1.7	5
74	Emerging drugs for the treatment of radioactive iodine refractory papillary thyroid cancer. Expert Opinion on Investigational Drugs, 2022, 31, 669-679.	1.9	1
75	Associations Between Plasma Concentrations of Lenvatinib and Angiopoietin and Clinical Responses to Lenvatinib Therapy in Japanese Patients With Thyroid Cancer. Cancer Diagnosis & Prognosis, 2022, 2, 336-344.	0.3	0
76	Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model. Biomedicines, 2022, 10, 1901.	1.4	1
77	The feasibility and efficacy of ultrasound-guided percutaneous laser ablation for multifocal papillary thyroid microcarcinoma. Frontiers in Endocrinology, 0, 13, .	1.5	6
78	Potential Therapeutic Agents against Paclitaxelâ€"And Sorafenib-Resistant Papillary Thyroid Carcinoma. International Journal of Molecular Sciences, 2022, 23, 10378.	1.8	3

#	Article	IF	Citations
79	Clinicopathologic Characteristics of Pediatric Follicular Variant of Papillary Thyroid Carcinoma Subtypes: A Retrospective Cohort Study. Thyroid, 2022, 32, 1353-1361.	2.4	1
80	Pathologic complete response after neoadjuvant v-Raf murine sarcoma viral oncogene homolog B (BRAF) inhibition combined with immunotherapy therapy for anaplastic thyroid carcinoma: a case report and literature review. Endocrine Journal, 2022, , .	0.7	1
81	HS3ST3A1 and CAPN8 Serve as Immune-Related Biomarkers for Predicting the Prognosis in Thyroid Cancer. Journal of Oncology, 2022, 2022, 1-14.	0.6	2
82	Molecular features of aggressive thyroid cancer. Frontiers in Oncology, 0, 12, .	1.3	7
83	Genome-wide association studies of cardiovascular disease. Physiological Reviews, 2023, 103, 2039-2055.	13.1	13
84	Integrated analysis of transcription factor-mRNA-miRNA regulatory network related to immune characteristics in medullary thyroid carcinoma. Frontiers in Immunology, 0, 13, .	2.2	2
85	Age-Dependent Clinicopathological Characteristics of Patients with T1b Papillary Thyroid Carcinoma: Implications for the Possibility of Active Surveillance. Annals of Surgical Oncology, 2023, 30, 2246-2253.	0.7	3
86	Do Histologically Aggressive Subtypes of Papillary Thyroid Microcarcinoma have Worse Clinical Outcome than Non-Aggressive Papillary Thyroid Microcarcinoma Subtypes? A Multicenter Cohort Study. Hormone and Metabolic Research, 0, , .	0.7	0
87	ASPM promotes migration and invasion of anaplastic thyroid carcinoma by stabilizing KIF11. Cell Biology International, 2023, 47, 1209-1221.	1.4	3
88	Anti-Cancer SERCA Inhibitors Targeting Sorafenib-Resistant Human Papillary Thyroid Carcinoma. International Journal of Molecular Sciences, 2023, 24, 7069.	1.8	5